Taiwan's biotech sector has hit a record market capitalization of $69 billion — yet commands just 1.4% of the island's total stock market, steadily crowded out as AI and semiconductor stocks absorbed the bulk of investor capital.
That imbalance drew attention at a biotech investment forum hosted by Quantitative Investment Consulting (QIC) in Taipei on August 25. QIC founder and CEO Lee Hung-chi argued that even a modest reallocation from technology stocks could reshape the sector's fortunes. "If just 1.5 percentage points of capital shifts from AI and semiconductor stocks into biotech," Lee said, "the sector's market cap would nearly double." The scenario assumes overall market stability and concentrated inflows, but Lee's point is that the sector's low weight creates an outsized sensitivity to even modest rotation.
Semiconductors Now Claim 75% of Taiwan's Stock Market
QIC senior adviser Wang Guan-ran traced the divergence to the generative AI boom. Since 2023, Taiwan's semiconductor and electronics supply chain has swelled to nearly 75% of total stock market capitalization, diluting biotech's share from a 2015 peak of 3.9% to the current 1.4% — a level last seen around 2012. The sector's absolute value has not shrunk; $69 billion is an all-time high. But growth has simply not kept pace.
The industry's breadth has expanded considerably. More than 250 companies now trade on Taiwan's capital markets, up from roughly 54 in 2007, spanning cell and gene therapies, drug delivery, contract development and manufacturing (CDMO), and medical AI. Wang argued that this depth makes biotech one of the few non-electronics sectors capable of absorbing significant capital rotation — and that its tendency to move on company-specific catalysts, rather than the semiconductor cycle, gives it diversification appeal in a tech-heavy market.
However, that same event-driven quality cuts both ways. A failed trial or delayed regulatory review can erase value as quickly as a positive outcome creates it, and the uneven scale, trading liquidity, and financial maturity of Taiwan's 250-plus biotech companies means any capital inflow would not distribute evenly across the sector.
FDA Decision on PharmaEssentia Leads a Packed Pipeline
A dense calendar of near-term events gives the rotation thesis something concrete to hang on. The most closely watched is a U.S. FDA ruling on BESREMi, PharmaEssentia's treatment for essential thrombocythemia, a blood platelet disorder. The agency's target review date was August 30; as of publication, no decision has been announced.
Further milestones follow through 2027. Taiwan Liposome Company expects Phase 3 results for a long-acting post-surgical pain drug by late September. Elixiron Immunotherapeutics is moving its CD36 monoclonal antibody for solid tumors into licensing discussions, while AnnJi Pharmaceutical plans to open a global Phase 3 trial for a Kennedy's disease treatment in the fourth quarter. Belite Bio targets February 2027 for Phase 3 data on a Stargardt disease therapy.
QIC was careful to frame these as catalysts, not certainties — clinical schedules and regulatory reviews can slip, and a win at one company would not lift the sector uniformly. The forum also featured presentations from five listed companies: Protect Animal Health on veterinary pharmaceuticals, EverFortune.ai on medical AI, Ever Supreme Bio Technology on CAR-T cell therapies, PharmaEssentia on commercialization, and Locus Cell on cell manufacturing for international clients.
From Dream Multiples Toward Commercial Revenue
Taiwan's biotech sector long carried the label 本夢比 — multiple expansion driven by optimistic projections rather than actual earnings. Wang pointed to PharmaEssentia as evidence of maturation: having secured international approvals and built its own U.S. sales force, it has moved beyond the licensing-dependent model that once defined Taiwanese biotech into self-sustaining commercial revenue.
Whether that transition scales across the sector will determine the rotation story's durability. A low market cap ratio signals room to grow, not that the sector is broadly undervalued. Drug approvals, licensing deals, and earnings are what ultimately attract capital — and, as Lee told the forum, what will separate lasting gains from a trade that fades with the headline.